1-7 of 7
Jorge Caicedo
Close
Sort by
Journal Articles

Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD

Robert F. Sidonio, Angela C Weyand, Tammuella Chrisentery-Singleton, Martin Chandler, Haduwa Momoh, Priscilla Driscoll-Shempp, Bethany Jones, Natalia Nieto, Jorge Caicedo
Journal: Blood
Blood (2023) 142 (Supplement 1): 2613.
https://doi.org/10.1182/blood-2023-174729
Published: 2023
Journal Articles

Identifying Ideal Individuals for PK-Guided Dosing; Recreational Risks and Elevated Breakthrough Bleeding

Guy Young, Vinod V. Balasa, Jonathan C. Roberts, Andrew Frick, Ali G Mokdad, Jorge Caicedo
Journal: Blood
Blood (2023) 142 (Supplement 1): 3742.
https://doi.org/10.1182/blood-2023-178042
Published: 2023
Journal Articles

Real-World Analysis of Healthcare Resource Utilization and Costs Among Patients Diagnosed with Von Willebrand Disease and Angiodysplasia

Nathan T. Connell, Jorge Caicedo, Natalia Nieto, Sagnik Chatterjee, Arunima Hait, Michael Bullano, Arun Gupta, Bob G Schultz
Journal: Blood
Blood (2022) 140 (Supplement 1): 7885–7886.
https://doi.org/10.1182/blood-2022-163760
Published: 2022
Journal Articles

Development of a Machine Learning Algorithm for Early Diagnosis of Persons with Von Willebrand Disease Using Real-World Data

Robert F. Sidonio, Jr., Anan Lu, Sarah Hale, Jorge Caicedo, Michael Bullano, Shan Xing
Journal: Blood
Blood (2022) 140 (Supplement 1): 2713–2714.
https://doi.org/10.1182/blood-2022-163819
Published: 2022
Journal Articles

Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset

Brian Hu, Martin Chandler, Matthew Manuel, Jorge Caicedo, Michael Denne, Bruce Ewenstein, Ali Mokdad, Shan Xing, Michael Recht
Journal: Blood
Blood (2022) 140 (Supplement 1): 2722–2723.
https://doi.org/10.1182/blood-2022-163861
Published: 2022
Journal Articles

A Real-World Study of Pre-Post Annualized Bleed Rates and All Cause Costs Among Non-Inhibitor Patients with Hemophilia a Switching from FVIII Prophylaxis to Emicizumab

Katharine Batt, Bob G Schultz, Jorge Caicedo, Christopher S Hollenbeak, Neha Agrawal, Sagnik Chatterjee, Megha Dayma, Michael Bullano
Journal: Blood
Blood (2021) 138 (Supplement 1): 3028.
https://doi.org/10.1182/blood-2021-146616
Published: 2021
Journal Articles

Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products

Janna M. Journeycake, MD, Michael Recht, MD PhD, Christine Guelcher, Hemostasis RN-BC, MS, PPCNP-BC, Ellis J. Neufeld, Margaret V. Ragni, MDMPH, Robert F. Sidonio, Jr., MDMSc, Cliff Takemoto, Michael D Tarantino, MD, Dunlei Cheng, PhD, Susan U. Lattimore, Jorge Caicedo, Michael Denne, PharmD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-138898
Published: 2020